07.26.10
Ambit Biosciences Announces Transition in Company Leadership

12.11.09
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia

12.07.09
Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients with Acute Myeloid Leukemia at ASH Conference

12.07.09
Ambit Biosciences Corporation Announces Two Poster Presentations Characterizing the Effects of AC220 in Preclinical Models of Acute Myeloid Leukemia at ASH Conference